A Study to Evaluate the Safety and Immunogenicity of Novel Oral Polio Vaccine
A Phase 2 Study to Evaluate the Safety and Immunogenicity of Two Novel Oral Polio Type 2 (nOPV2) Vaccine Candidates in Healthy Children Aged 1 to 5 Years and in Healthy Bivalent Oral Polio Vaccine-inactivated Polio Vaccine (bOPV-IPV) Vaccinated Infants
Sponsor: Bill and Melinda Gates Foundation
Listed as NCT03554798, this PHASE2 trial focuses on Poliomyelitis and remains completed. Sponsored by Bill and Melinda Gates Foundation, it has been updated 11 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Feb 2024 — Jul 2024 [monthly]
Completed PHASE2
-
Apr 2022 — Feb 2024 [monthly]
Completed PHASE2
▶ Show 6 earlier versions
-
Jan 2021 — Apr 2022 [monthly]
Completed PHASE2
-
Aug 2020 — Jan 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Mar 2020 — Aug 2020 [monthly]
Active Not Recruiting PHASE2
-
Oct 2019 — Mar 2020 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2019 — Oct 2019 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jul 2018 — Jan 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Bill and Melinda Gates Foundation
- Fidec Corporation
For direct contact, visit the study record on ClinicalTrials.gov .